#USA #Waltham #cancer detection #Mercy BioAnalytics #Darrin Crisitello

Mercy BioAnalytics Appoints Darrin Crisitello as Chief Commercial Officer

Mercy BioAnalytics, a leader in the field of cancer detection, has announced the appointment of Darrin Crisitello as its new Chief Commercial Officer (CCO). With a focus on amplifying the company's commercial strategies, Crisitello is expected to play a pivotal role in driving sales and partnerships as Mercy prepares to introduce its innovative oncology products to the market.

Crisitello's appointment comes at a crucial time for Mercy BioAnalytics, which is renowned for its advancements in cancer detection technology. His extensive experience spans over two decades in the diagnostics, life sciences, and healthcare technology sectors. This experience includes the successful launch of various diagnostic products across oncology, neurology, and women’s health, which should serve him well in his new role.

Dawn Mattoon, the Chief Executive Officer of Mercy, expressed optimism about Crisitello's leadership. She noted, "Darrin is a proven commercial leader with a rare combination of strategic vision and hands-on execution. His experience in commercializing groundbreaking diagnostic technologies and building high-performance teams will be instrumental in our efforts to expand access to our cancer detection tests and fulfill our mission of enhancing patient outcomes through earlier diagnosis."

Prior to joining Mercy, Crisitello served as the Chief Commercial Officer at Quanterix. In that role, he led initiatives to commercialize platforms for ultra-sensitive biomarker detection, which are crucial for early disease identification, particularly in neurology and oncology. His past positions also include senior leadership roles at Natera, where he contributed to the launch of the Panorama® non-invasive prenatal test and supported the company through its initial public offering in 2015, as well as at Color Health, where he aided in market expansion.

"I am thrilled to join Mercy at such a pivotal stage," Crisitello stated. "The science behind Mercy’s products has the potential to significantly alter the landscape of cancer detection and management. I look forward to collaborating with the team to ensure these advancements reach the clinicians and patients who need them most."

Crisitello holds a Bachelor of Science degree in Biology and Chemistry from Moravian College and an MBA from the University of Massachusetts. His commitment to enhancing cancer detection methods highlights his dedication to improving patient outcomes.

About Mercy BioAnalytics

Mercy BioAnalytics is dedicated to minimizing suffering and saving lives through early cancer detection. Although early-stage cancer can be challenging to diagnose, timely detection often allows for curative therapies. The company's proprietary Mercy Halo™ liquid biopsy platform utilizes innovative biomarker co-localization technology to analyze blood-derived extracellular vesicles that convey unique cancer markers from their originating cells. This technology is aimed at identifying early-stage cancers, facilitating timely intervention, and ultimately improving the quality of life for patients and their families.

Currently, Mercy BioAnalytics is particularly focused on the early detection of ovarian and lung cancers, which are among the most lethal forms of cancer. Ovarian cancer, known as the deadliest gynecological cancer, frequently goes undetected until it is too late for effective treatment. Lung cancer, on the other hand, is responsible for more deaths than breast and prostate cancers combined.

For more detailed information about Mercy BioAnalytics and its innovative approaches to cancer detection, visit their official website at www.mercybio.com.